Article Abstract

Neoadjuvant therapy for pancreatic ductal adenocarcinoma—real effects or patient selection?

Authors: Stefan Heinrich


Surgery is the only treatment with curative potential for patients with pancreatic ductal adenocarcinoma (PDAC). Unfortunately, the majority of patients do not qualify for curative resection due to locally advanced or metastatic disease at presentation.